In the VARIATION study, T2D patients under combination therapy of basal insulin with a GLP-1 RA reach well glycemic control and the lowest glucose variability, comparing with subjects with other common insulin therapy regimens including premixed contents. The gene discussed is GCG; the disease is type 2 diabetes mellitus.